Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from bioAffinity Technologies, Inc. ( (BIAF) ).
On September 3, 2025, bioAffinity Technologies announced that U.S. Medicine Magazine featured their CyPath® Lung test in its pulmonary issue, recognizing its potential to enhance lung cancer detection and reduce costs for the Department of Veterans Affairs. The test has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, with significant potential savings for healthcare systems by reducing unnecessary follow-up procedures. This recognition underscores the test’s value in improving patient outcomes and its economic benefits, particularly for veterans at higher risk of developing lung cancer.
The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The overall stock score of 47 reflects significant financial challenges and a bearish technical outlook, partially offset by positive corporate events. The company’s financial performance is the most significant factor, with negative profitability and increasing leverage weighing heavily on the score. Technical analysis and valuation also contribute to the low score, while recent corporate events provide some positive momentum.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a company focused on noninvasive diagnosis of early-stage cancer and other lung diseases, as well as broad-spectrum cancer treatments. Their first product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Average Trading Volume: 4,475,871
Technical Sentiment Signal: Sell
Current Market Cap: $6.89M
See more data about BIAF stock on TipRanks’ Stock Analysis page.